Memorial Sloan-Kettering Cancer Center, New York City, U.S.

Radical surgery for kidney cancer is a risk factor for chronic kidney disease

Published in Pharma Law Weekly, September 26th, 2006

For forty years, the gold standard for treating a single, small tumor in the kidney has been to remove the entire kidney. A retrospective study, which appears in a recent issue of The Lancet Oncology, by urologists at Memorial Sloan-Kettering Cancer Center (MSKCC) and their colleagues, suggests that partial removal may be a more successful method in today's healthcare environment.

Researchers add that with advances in imaging, almost 70% of kidney cancer patients have their tumor detected at a very small size (less than 4 cm), allowing surgeons to perform less radical surgery with superior results.

The study revealed that patients with two...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2006-09-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry